Abstract：
Research into cancer therapeutics has uncovered various potential medications based on metal-containing scaffolds after the discovery and clinical applications of cisplatin as an anti-cancer agent. This has resulted in many metallodrugs that can be put into medical applications. These metallodrugs have a wider variety of functions and mechanisms of action than pure organic molecules. Although platinum-based medicines are very efficient anti-cancer agents, they are often accompanied by significant side effects and toxicity and are limited by resistance. Some of the most studied and developed alternatives to platinum-based anti-cancer medications include metallodrugs based on ruthenium, gold, copper, iridium, and osmium, which showed effectiveness against many cancer cell lines. These metal-based medicines represent an exciting new category of potential cancer treatments and sparked a renewed interest in the search for effective anti-cancer therapies. Despite the widespread development of metal complexes touted as powerful and promising in vitro anti-cancer therapeutics, only a small percentage of these compounds have shown their worth in vivo models. Metallodrugs, which are more effective and less toxic than platinum-based drugs and can treat drug-resistant cancer cells, are the focus of this review. Here, we highlighted some of the most recently developed Pt, Ru, Au, Cu, Ir, and Os complexes that have shown significant in vivo antitumor properties between 2017 and 2023.
摘要：
在发现和临床应用顺铂作为抗癌剂后，对癌症疗法的研究已经发现了基于含金属支架的各种潜在药物。这导致了许多金属药物可以用于医学应用。这些金属药物比纯有机分子具有更广泛的功能和作用机制。尽管铂类药物是非常有效的抗癌药物，它们通常伴有明显的副作用和毒性，并且受到耐药性的限制。铂类抗癌药物的一些研究和开发最多的替代品包括基于钌的金属药物，黄金,铜，铱,和锇,这显示了对许多癌细胞系的有效性。这些基于金属的药物代表了一种令人兴奋的潜在癌症治疗新类别，并引发了人们对寻找有效抗癌疗法的新兴趣。尽管被吹捧为强大且有前途的体外抗癌疗法的金属配合物得到了广泛的发展，这些化合物中只有一小部分在体内模型中显示出它们的价值。金属药物,比铂类药物更有效，毒性更小，可以治疗耐药癌细胞，是本次审查的重点。这里,我们强调了一些最新开发的铂，Ru,Au,Cu,Ir,和Os复合物在2017年至2023年之间显示出显著的体内抗肿瘤特性。
